TWI742541B - 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 - Google Patents

用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 Download PDF

Info

Publication number
TWI742541B
TWI742541B TW109106077A TW109106077A TWI742541B TW I742541 B TWI742541 B TW I742541B TW 109106077 A TW109106077 A TW 109106077A TW 109106077 A TW109106077 A TW 109106077A TW I742541 B TWI742541 B TW I742541B
Authority
TW
Taiwan
Prior art keywords
compound
fibrosis
salt
skin
pharmaceutically acceptable
Prior art date
Application number
TW109106077A
Other languages
English (en)
Chinese (zh)
Other versions
TW202045469A (zh
Inventor
萊恩 加格諾
皮爾瑞 拉瑞琳
布萊吉特 格洛克斯
里萊尼 吉爾特斯
布爾尼特 法蘭西斯 莎拉
馬丁 李達克
尚恩 亞伯特
珍 法蘭西斯 班佛奴
瓦勒里 佩容
波洛斯 薩賈瑞
Original Assignee
英商邊緣生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商邊緣生物科技有限公司 filed Critical 英商邊緣生物科技有限公司
Publication of TW202045469A publication Critical patent/TW202045469A/zh
Application granted granted Critical
Publication of TWI742541B publication Critical patent/TWI742541B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW109106077A 2013-03-15 2014-03-12 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 TWI742541B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798427P 2013-03-15 2013-03-15
US61/798,427 2013-03-15

Publications (2)

Publication Number Publication Date
TW202045469A TW202045469A (zh) 2020-12-16
TWI742541B true TWI742541B (zh) 2021-10-11

Family

ID=51535670

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109106077A TWI742541B (zh) 2013-03-15 2014-03-12 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
TW103108714A TWI689489B (zh) 2013-03-15 2014-03-12 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW103108714A TWI689489B (zh) 2013-03-15 2014-03-12 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物

Country Status (25)

Country Link
US (3) US9884802B2 (OSRAM)
EP (1) EP2970088B1 (OSRAM)
JP (1) JP6381557B2 (OSRAM)
KR (1) KR102303493B1 (OSRAM)
CN (1) CN105143170B (OSRAM)
AR (1) AR095427A1 (OSRAM)
AU (1) AU2014231649C1 (OSRAM)
BR (1) BR112015023129A2 (OSRAM)
CA (1) CA2905633C (OSRAM)
CL (1) CL2015002725A1 (OSRAM)
DK (1) DK2970088T3 (OSRAM)
EA (1) EA031511B1 (OSRAM)
ES (1) ES2780825T3 (OSRAM)
IL (1) IL241164B (OSRAM)
MX (1) MX375261B (OSRAM)
MY (1) MY194727A (OSRAM)
NZ (1) NZ712745A (OSRAM)
PH (1) PH12015502012A1 (OSRAM)
PL (1) PL2970088T3 (OSRAM)
PT (1) PT2970088T (OSRAM)
SG (1) SG11201507274PA (OSRAM)
TW (2) TWI742541B (OSRAM)
UY (1) UY35401A (OSRAM)
WO (1) WO2014138907A1 (OSRAM)
ZA (1) ZA201507062B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
MX376873B (es) * 2014-10-10 2025-03-07 Liminal Biosciences Ltd Compuestos aromaticos sustituidos y composiciones farmaceuticas para la prevencion y tratamiento de osteoporosis.
JP6720169B2 (ja) * 2014-11-12 2020-07-08 リミナル・バイオサイエンシーズ・リミテッドＬｉｍｉｎａｌ ＢｉｏＳｃｉｅｎｃｅｓ Ｌｉｍｉｔｅｄ 組織の自己修復及び再生のための置換芳香族化合物及び医薬組成物
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
HK1250345A1 (zh) 2015-05-13 2018-12-14 Afimmune Limited 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
US10046007B2 (en) * 2015-06-24 2018-08-14 Prescient Pharma, Llc Compositions and methods for treatment of short telomere disorders
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
WO2019096944A1 (en) * 2017-11-15 2019-05-23 Galapagos Nv Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
US20210205253A1 (en) * 2018-05-31 2021-07-08 The Asan Foundation Use Of Stearic Acid For Preventing Or Treating Pulmonary Fibrosis
MA53188A1 (fr) 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques
US20220016060A1 (en) * 2018-12-05 2022-01-20 Liminal Biosciences Limited Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alström syndrome
EP3908668A4 (en) 2019-01-11 2022-11-09 University of Virginia Patent Foundation COMPOSITIONS AND METHODS FOR PREDICTING LUNG FUNCTION DECLINE RELATED TO IDIOPATHIC PULMONARY FIBROSIS
WO2020181163A1 (en) * 2019-03-06 2020-09-10 Tobira Therapeutics, Inc. Lipid-based formulation of cenicriviroc
WO2021015218A1 (ja) * 2019-07-24 2021-01-28 国立大学法人九州大学 転写関連因子を標的とする線維化疾患の予防または治療
CN112441916A (zh) * 2019-08-29 2021-03-05 广东药科大学 新型苯乙酸衍生物、其制备方法及其作为药物的用途
MX2023004137A (es) * 2020-10-06 2023-06-22 Pharmaceutique Ingenew Inc Compuestos aromaticos sustituidos y composiciones farmaceuticas de los mismos.
US12053467B2 (en) * 2020-12-18 2024-08-06 NovMeta Pharma Co., Ltd. Method of treating fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20012434A1 (it) 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
BRPI1015118A2 (pt) * 2009-05-04 2016-04-12 Prometic Biosciences Inc sais de ácido pentilfenilacético e usos farmacêuticos dos mesmos
PT2427416E (pt) * 2009-05-04 2016-06-15 Prometic Pharma Smt Ltd Compostos aromáticos substituídos e seus usos farmacêuticos
SG10201807622WA (en) 2010-10-27 2018-10-30 Prometic Pharma Smt Ltd Compounds and compositions for the treatment of cancer
CN102070433B (zh) * 2010-12-27 2013-03-27 桂林师范高等专科学校 芳香基乙酸类衍生物的制备方法
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
JP6720169B2 (ja) * 2014-11-12 2020-07-08 リミナル・バイオサイエンシーズ・リミテッドＬｉｍｉｎａｌ ＢｉｏＳｃｉｅｎｃｅｓ Ｌｉｍｉｔｅｄ 組織の自己修復及び再生のための置換芳香族化合物及び医薬組成物

Also Published As

Publication number Publication date
WO2014138907A1 (en) 2014-09-18
US9884802B2 (en) 2018-02-06
MX2015012886A (es) 2016-04-04
MX375261B (es) 2025-03-06
MY194727A (en) 2022-12-15
EP2970088A4 (en) 2016-10-19
US20160023983A1 (en) 2016-01-28
US20180134649A1 (en) 2018-05-17
CN105143170B (zh) 2019-11-08
US10450258B2 (en) 2019-10-22
JP2016510769A (ja) 2016-04-11
EA031511B1 (ru) 2019-01-31
BR112015023129A2 (pt) 2017-07-18
AR095427A1 (es) 2015-10-14
EA201591774A1 (ru) 2015-12-30
DK2970088T3 (da) 2020-03-30
PL2970088T3 (pl) 2020-11-02
IL241164A0 (en) 2015-11-30
SG11201507274PA (en) 2015-10-29
AU2014231649A1 (en) 2015-10-22
CN105143170A (zh) 2015-12-09
US20200017432A1 (en) 2020-01-16
AU2014231649C1 (en) 2018-08-23
PH12015502012A1 (en) 2016-01-11
PT2970088T (pt) 2020-03-27
ZA201507062B (en) 2017-04-26
NZ712745A (en) 2020-06-26
CA2905633C (en) 2021-12-28
JP6381557B2 (ja) 2018-08-29
ES2780825T3 (es) 2020-08-27
CA2905633A1 (en) 2014-09-18
UY35401A (es) 2014-10-31
AU2014231649B2 (en) 2018-01-04
EP2970088A1 (en) 2016-01-20
US11267779B2 (en) 2022-03-08
EP2970088B1 (en) 2020-01-01
KR102303493B1 (ko) 2021-09-16
CL2015002725A1 (es) 2016-04-15
TWI689489B (zh) 2020-04-01
TW201441185A (zh) 2014-11-01
KR20160040452A (ko) 2016-04-14
TW202045469A (zh) 2020-12-16
IL241164B (en) 2020-11-30
HK1220439A1 (en) 2017-05-05

Similar Documents

Publication Publication Date Title
TWI742541B (zh) 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
US11524930B2 (en) Substituted aromatic compounds and related method for the treatment of fibrosis
HK1220439B (en) Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis
HK1220440B (en) Substituted aromatic compounds

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees